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Abstract 
Background: Ghana has developed two main community‑based strategies that aim to increase access to quality 
treatment for malaria, diarrhoea and suspected pneumonia: the integrated community case management (iCCM) and 
the community‑based health planning and services (CHPS). The aim of the study was to assess the cost‑effectiveness 
of these strategies under programme conditions.
Methods: A cost‑effectiveness analysis was conducted. Appropriate diagnosis and treatment given was the effec‑
tiveness measure used. Appropriate diagnosis and treatment data was obtained from a household survey conducted 
2 and 8 years after implementation of iCCM in the Volta and Northern Regions of Ghana, respectively. The study 
population was carers of children under‑5 years who had fever, diarrhoea and/or cough in the last 2 weeks prior to 
the interview. Costs data was obtained mainly from the National Malaria Control Programme (NMCP), the Ministry of 
Health, CHPS compounds and from a household survey.
Results: Appropriate diagnosis and treatment of malaria, diarrhoea and suspected pneumonia was more cost‑
effective under the iCCM than under CHPS in the Volta Region, even after adjusting for different discount rates, facility 
costs and iCCM and CHPS utilization, but not when iCCM appropriate treatment was reduced by 50%. Due to low 
numbers of carers visiting a CBA in the Northern Region it was not possible to conduct a cost‑effectiveness analysis 
in this region. However, the cost analysis showed that iCCM in the Northern Region had higher cost per malaria, diar‑
rhoea and suspected pneumonia case diagnosed and treated when compared to the Volta Region and to the CHPS 
strategy in the Northern Region.
Conclusions: Integrated community case management was more cost‑effective than CHPS for the treatment of 
malaria, diarrhoea and suspected pneumonia when utilized by carers of children under‑5 years in the Volta Region. A 
revision of the iCCM strategy in the Northern Region is needed to improve its cost‑effectiveness. Long‑term financing 
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Background
In December 2014 a new global coalition of more than 
500 leading health and development organizations 
worldwide was launched to urge governments to acceler-
ate reforms that ensure everyone, everywhere, can access 
quality health services without being forced into poverty 
[1]. This global coalition, called the Universal Health 
Coverage (UHC), comprises two main components: qual-
ity essential health service coverage and financial cover-
age—both extended to the whole population [2].
With UHC on the global health agenda, governments 
of many low and middle-income countries are under 
pressure to scale up essential health services to meet the 
needs of their people. This means that governments need 
to prioritize effective interventions to scale up. Health 
technology assessments (HTAs) have been recognized 
as a tool for priority setting particularly useful in this 
UHC context [3]. HTA examines the cost-effectiveness 
of an intervention as well as the organizational implica-
tions and social consequences, bridging the gap between 
the evidence and policy making [4]. HTA can be used to 
prioritize an intervention in a particular context as men-
tioned before (ex-ante HTA) or it can be used as a moni-
toring tool, providing information to governments and 
funders to continue or discontinue certain interventions, 
helping to address sustainability (ex-post HTA) [3, 4].
Ghana has developed two main community based 
strategies that aim to reduce barriers to physical access to 
quality treatment: the iCCM and CHPS. Both strategies 
are implemented in the ten regions of Ghana through 
the Ghana Health Service and under the umbrella of 
the Ministry of Health. The iCCM strategy (then called 
home-based care) started on a pilot basis in Ghana in 
1999 to treat suspected malaria cases [5]. The pilot pro-
gramme initially used chloroquine, shifting to arte-
misinin-based combination therapy (ACT) in 2005 [6]. 
In 2009 and in the context of integrated management of 
childhood illness (IMCI), Ghana developed the Home 
Management of Malaria, ARI and Diarrhoea in Ghana 
[5]. iCCM was defined as prevention, early case detec-
tion and prompt and appropriate treatment of fevers, 
ARI and diarrhoea in the community. The iCCM strategy 
corresponds to the lowest level of health care delivery in 
Ghana and it is implemented through community-based 
agents (CBAs) selected by the community which received 
a 5-days training. The iCCM guidelines states that the 
service provided by the CBAs should be free [5] although 
some regions decided that users should give an small 
amount of money to CBAs to avoid risking continuity of 
the strategy. The HBC current funding is primarily reliant 
on external multilateral and bilateral donors as in many 
other countries [7–12]. The long-term financial plan for 
iCCM in Ghana is not clear.
The CHPS strategy started in 1999 after a pilot phase 
conducted in 1994 [13] attempting to respond to the 1978 
Alma Ata Conference and the ‘Health for All’ principle. 
A key component of the CHPS strategy is that traditional 
leaders of the community must accept the CHPS concept 
and commit themselves to supporting it. The CHPS strat-
egy is based upon a basic facility known as a community 
health compound, where health care is provided by a resi-
dent community health nurse or community health officer 
who also does a 90-day cycle visiting the communities 
she/he serves at least once within that period. Commu-
nity health nurses receive formal training for a minimum 
of 2 years. Services provided by accredited CHPS are free 
for those having an active national insurance card.
After several years of national implementation, it 
is important to know how effective and cost-effective 
iCCM and CHPS are at delivering preventive and cura-
tive health services known to contribute to reducing the 
morbidity and mortality of children under-five. Stud-
ies that have looked at the effect of the iCCM in Ghana 
mostly focused in a few districts, looked particularly at 
the management of malaria home-based care, neglect-
ing the cost-effectiveness and the preventive compo-
nent, and were conducted in a more “controlled” context 
[14–18]. Ferrer et  al. [19] reported on the utilization, 
effectiveness and users’ satisfaction of the curative com-
ponent of iCCM and CHPS. This paper presents a cost-
effectiveness analysis of iCCM versus CHPS. This study 
is an approach to ex-post HTA which considers the real 
costs and effectiveness of both interventions (iCCM and 
CHPS) which is key to policy decisions. Results from this 
study may be used to improve performance and to guide 
decisions on sustainable financing strategies particularly 
regarding iCCM.
Methods
Study site
The Volta and Northern Regions were purposively 
selected. Criteria for selecting these regions are described 
strategies should be explored including potential inclusion in the National Health Insurance Scheme (NHIS) benefit 
package. An acceptability study of including iCCM in the NHIS should be conducted.
Keywords: Home‑ based care, Integrated community case management (iCCM), Malaria, Diarrhoea, Pneumonia, 
Children under‑five, Cost‑effectiveness analysis
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in Ferrer et  al. [19]. In brief, the first criteria was the 
inclusion of a region implementing iCCM but providing 
only treatment for malaria and a region providing treat-
ment for malaria, diarrhoea and pneumonia, to have a 
better picture of the iCCM strategy in Ghana. The second 
criteria was different implementation performance lev-
els, based on the routine information system. The CHPS 
strategy is uniform across all ten regions of the country. 
The iCCM in the Volta Region was supported mainly 
through the Global Fund and targeted only rural dis-
tricts for the iCCM implementation. Volta Region had a 
population of 1,901,179 habitants, 17 districts, 674 CHPS 
and 920 CBAs in 2014; malaria prevalence was 17%, diar-
rhoea prevalence was 7.6% and suspected pneumonia 
prevalence was 2.1% in children under-five [20]. The rural 
population corresponded to 66% of the total population. 
Two rainfall seasons occur in the middle and coastal 
belts. One major season is in April/July with a peak in 
June and one minor season is in September/November 
with a peak in October. The north of Volta Region has 
one rainy season—May to October with a peak in August.
The iCCM in the Northern Region was supported 
mainly through UNICEF and targeted all communities. 
It had a population of 2,479,461 habitants, 20 districts, 
210 CHPS and 5000 CBAs in 2014; malaria prevalence 
was 48%, diarrhoea prevalence was 21.4% and suspected 
pneumonia prevalence was 6.3% in children under five 
[21]. The rural population corresponded to 70% of the 
total population. In the north, the rainy season begins in 
May and ends in October [22]. Climatically, religiously, 
linguistically, and culturally, the Northern Region differs 
greatly from the politically and economically dominating 
regions of central and southern Ghana, and it is similar 
to the two other northern regions (Upper East and Upper 
West).
Measurement of effect
The effectiveness measure used was ‘case appropriately 
diagnosed and treated’. This refers to a malaria, diar-
rhoea or suspected pneumonia case that received treat-
ment according to treatment guidelines (Table  1) or a 
child without malaria, diarrhoea or suspected pneumo-
nia that was not prescribed the recommended drugs to 
treat malaria, diarrhoea or pneumonia. Definitions of 
a malaria, diarrhoea and suspected pneumonia case are 
presented in Table  1. Appropriate diagnosis and treat-
ment is a proxy indicator of child mortality. Malaria cases 
can progress rapidly to complication and death if malaria 
treatment is not administered in the first 24–48 h from 
onset of symptoms [23]. Prompt treatment with a full 
course of effective antibiotics is key to reduce pneumonia 
deaths [24]. ORS and zinc are effective therapeutic inter-
ventions to reduce diarrhea mortality [25].
Data from a cross sectional household survey was used 
to assess the number of cases appropriately diagnosed 
and treated under the iCCM and CHPS [19]. In brief, a 
stratified three stage cluster survey was conducted in the 
Volta and Northern Regions. In order for the sample to 
be representative of the whole region, whilst being logis-
tically feasible, regions were divided into three areas. 
From each area, two districts and from each district four 
clusters were selected using probability proportional 
to size. Then, from each cluster 27 households were 
selected, making a total of 648 households in each region. 
To select the districts (first stage) the list of districts 
implementing HBC (all districts implement the CHPS 
strategy) with its population was used. According to the 
NMCP, from the 24 districts in the Volta Region, only 
eight were targeted for the implementation of iCCM and 
these comprised the sampling frame. In the Northern 
Region all districts and communities were included in the 
sampling frame, as iCCM was implemented everywhere. 
To select the clusters (second stage) the list of commu-
nities implementing iCCM with its population was used. 
Then, households with children under-five that had fever, 
diarrhoea or cough in the last 2 weeks prior to the inter-
view were randomly selected in each cluster using a mod-
ified expanded programme on immunizations sampling 
technique (third stage) [26]. To select households, a loca-
tion near the centre of the community was first identified 
and a random direction was defined by spinning a pen. 
A random household along the chosen direction point-
ing outwards from the centre of the community to its 
boundary was chosen and checked for compliance with 
the inclusion and exclusion criteria. Whether the criteria 
were met or not, the next closest household was visited 
until the required number of households with a child 
with a fever, diarrhoea or cough in the 2 weeks preced-
ing the survey were surveyed. Interviews were conducted 
with the carer of the sick child. In cases where there was 
more than one eligible child in a household, only one of 
them was selected randomly by ballot paper.
Data collection was done using a structured question-
naire which included socio-demographic information of 
the carer, care-seeking behaviour, treatment received and 
source of treatment, experience with health providers 
and costs involved when seeking care.
Measurement of costs
Economic costing was done from the societal perspec-
tive, which considers costs from the perspective of 
households and the health system. The societal perspec-
tive is broader than the health system or government 
budget perspective [27], and allows comparison with pre-
vious studies. It is important to consider household costs 
because they can be significant, they may deter caregivers 
Page 4 of 18Escribano Ferrer et al. Malar J  (2017) 16:277 
from using a service and they might be a cause of poverty 
(catastrophic cost). Data on cost was collected from the 
household survey, the Health Administration and Sup-
port Services division (HASS) of the Ghana Health Ser-
vice, the National Malaria Control Programme, CHPS 
and from the NGO Plan International which supports 
HBC in the Volta Region. Unit cost was defined as the 
total cost incurred in diagnosing and treating one case of 
malaria, diarrhoea or suspected pneumonia.
Two activities were used to calculate the cost per case 
diagnosed and treated: (1) estimation of unit cost for 
treating a malaria, diarrhoea and suspected pneumo-
nia case from the iCCM, CHPS, and households and (2) 
combination of unit cost for treating a malaria, diarrhoea 
and suspected pneumonia case under the iCCM and 
CHPS strategies with the household costs to obtain unit 
cost from the societal perspective.
Estimation of unit costs for treating a malaria, diarrhoea 
and suspected pneumonia case from the iCCM, CHPS 
and households
iCCM costs
Costs per diagnosing and treating a malaria, diarrhoea 
and suspected pneumonia case under the iCCM strategy 
were divided into direct and indirect costs. Direct costs 
referred to those involved directly in the service. Indirect 
costs referred to productivity loses due to the time a CBA 
spent away from their usual activities (attending a sick 
child). Direct recurrent costs included training of CBAs 
(according to policy it happens every 2  years), train-
ing of supervisors (according to policy it happens every 
2  years), supervision (every year), training material for 
supervisors and CBAs and IEC material for CBAs (last 
several years), registers (every year) and cost of drugs 
(every year). Direct capital costs included ARI timers 
(to measure the breath rate to diagnose suspected pneu-
monia cases), box to keep CBA items and the incentive 
package (includes bicycles, raincoats, boots, torchlights 
and t-shirts) which, according to policy, is given once at 
the beginning of the intervention to motivate CBAs.
With regards to the Volta Region, Plan International 
provided information on cost for training CBAs and 
supervisors. Training expenditures were annualized 
using the expected life time of 2  years and the recom-
mended discount rate of 3%. Annualizing capital costs 
means that even though a good has been purchased at a 
specific point in time, one needs to consider that its ben-
efits will be enjoyed over several years, and therefore, its 
Table 1 Study definitions and treatment guidelines
a ARI timers are available in the Northern Region under the iCCM strategy to help diagnose suspected pneumonia. If severe pneumonia is suspected, the child must 
be referred to a CHPS compound or a Health Centre
b Nurses at CHPS compounds do not have ARI timers. The diagnosis is made based on clinical signs. If a severe pneumonia case is suspected, the children must be 
referred to a higher level of health facility. Some district hospitals, all regional hospitals and teaching hospitals have X-rays to help diagnose pneumonia. Health 
centres, district hospitals, regional hospitals and teaching hospitals have laboratory facilities to help diagnose malaria, diarrhoea and pneumonia
Definitions iCCM [5] CHPS [52]
Malaria All fever cases when no laboratory tests are available All fever cases when no laboratory tests are available or 
when malaria test was positive
Appropriate treatment of 
malaria
Children aged 6 months to 5 years diagnosed with malaria 
receiving 3 days of ACT
Children aged 2 months to 5 years diagnosed with 
malaria receiving 3 days of ACT
If more than 7 days with fever, general danger signs or 
severe malaria signs, child must be referred with rectal 
artesunate
If more than 7 days with fever, general danger signs or 
severe malaria signs, child must be referred with IM 
quinine, IM or EV or rectal artesunate plus an IM dose 
of chloramphenicol
Prompt treatment of malaria Malaria cases that received an antimalarial drug in within the 
first 24 h of the onset of symptoms
The same definition as in iCCM
Diarrhoea 3 or more loose or watery stools in a 24‑h period The same definition as in iCCM
Appropriate treatment of 
diarrhoea
Children older than 6 months with diarrhoea of less than 
7 days that receive ORS and zinc for 14 days
Children with diarrhoea of less than 14 days receiving 
ORS and zinc for 14 days
If the child is less than 6 months, had diarrhoea for 7 days or 
more, blood in stools or is dehydrated, he/she should be 
referred with ORS
If diarrhoea for 14 days or more, blood in stools or is 
severely dehydrated, he/she should be referred to 
hospital with ORS
ARI or suspected pneumonia Cough with fast or difficult  breathinga The same definition as in  HBCb
Appropriate treatment for 
suspected pneumonia
Children older than 6 months with cough and fast or dif‑
ficult breathing of less than 7 days receiving amoxicillin 
for 5 days
Children older than 2 months with cough and fast 
or difficult breathing of less than 14 days receiving 
amoxicillin or co‑trimoxazol for 5 days
If the child is less than 6 months or had symptoms for 7 days 
or more, he/she should be referred
If the child is less than 2 months or had symptoms for 
14 days or more, he/she should be referred
If there are signs of severe pneumonia, he/she should be 
referred with amoxicillin
If there are signs of severe pneumonia, he/she should 
be referred with IM chloramphenicol
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costs will be spread over these years. The directorate of 
the Volta Region provided information on the quantities 
of training material, registers, boxes and incentive pack-
age received from the national level, while the national 
level provided information about the cost per item sent 
to the regions. A 10% of freight costs were added to the 
unit costs. The training and IEC materials, the boxes and 
the incentive package are supposed to last several years, 
and therefore, they were annualized using the expected 
life time of 8 years and the discount rate of 3% [31]. The 
NMCP reported no ARI timers in the Volta Region. The 
number of drugs used in 2014 was obtained from the 
DHIMS2. The cost of drugs used was the median price 
from a list of suppliers obtained from the International 
Drug Price Indicator Guide [36] with an addition of 10% 
freight costs as when calculating CHPS costs.
The regional directorate of the Northern Region pro-
vided information about costs of training CBAs and 
supervisors. Training expenditures were annualized 
using the expected life time of 2  years and the recom-
mended discount rate of 3% [31]considering that, accord-
ing to policy, these trainings happen every 2  years. The 
directorate of the Northern Region provided informa-
tion on the quantities of training and IEC material, reg-
isters, boxes and incentive package received from the 
national level, while the national level provided informa-
tion about the cost per item sent to the regions. To these 
item cost, a 10% of freight costs were added. The train-
ing materials, the boxes and the incentive package were 
annualized using the expected life time of 8 years and the 
recommended discount rate of 3% as I did for the Volta 
Region. The unit cost of ARI timers used was US$3.5 plus 
a 10% of freight costs as recommended by UNICEF. The 
number of drugs used in 2014 was obtained from the 
DHIMS2. The cost of drugs used was the median price 
from a list of suppliers obtained from the International 
Drug Price Indicator Guide [36] with an addition of 10% 
freight costs as when calculating CHPS costs and iCCM 
costs in the Volta Region.
As indirect cost, the time of the CBAs attending a 
sick child was included. The opportunity cost to their 
time was estimated from interviews with four CBAs, 
two in each region. CBA time was assigned a monetary 
value based on the agricultural labour wage the main 
occupation of the population, particularly in rural areas 
[28]—which was 0.41  GHC/h [29, 30]. One GHC was 
equivalent to US$ 0.31 in 2014. All costs were estimated 
for 2014 and were converted to US dollars. Direct and 
indirect costs were allocated to malaria, diarrhoea and 
suspected pneumonia case management based on the 
percentage of iCCM activity reported in 2014 through 
the DHIMS-II.
CHPS costs
Two CHPS compounds were visited in each region to col-
lect information during the 5th to 16th April 2014 in the 
Volta Region and during the 23rd June to 3rd July 2014 
in the Northern Region. The criteria used to select these 
facilities was average performing facilities based on their 
activity (outpatient visit per nurse). This information was 
provided by the regional directorates. In addition, as cost 
information was collected during the household survey, 
the criteria of feasibility was also considered. This means 
that to select two CHPS among average CHPS, those that 
were closer to the communities being surveyed were con-
sidered. Two CHPS compounds were selected in Hohoe 
district (Volta Region), one in Central Gonja district 
(Northern Region) and one in Tolon-Kumbugu district 
(Northern Region).
Direct cost were considered from the CHPS perspec-
tive, including recurrent and capital costs (Table  2). 
As recurrent cost, salaries of personnel including any 
allowances received, medicines, disposables, stationary, 
utilities and maintenance costs were considered. 2014 
recurrent expenditures were obtained from the financial 
officer at the respective health districts. Capital cost were 
the building, vehicles, furniture and equipment that were 
annualized using the expected life time of 30, 8, 10 and 
8 years, respectively, and the recommended discount rate 
of 3% [31]. The size of the CHPS facilities was estimated 
based on plans of standard CHPS facilities available from 
the HASS division. The information on construction cost 
per  m2 for such buildings was obtained from the same 
division. An inventory of equipment and furniture was 
developed during the field visits at the two CHPS in each 
region. These items were valued using a price list from 
the HASS division. If the cost of an existing equipment 
or furniture was not in the list provided by the HASS 
division, market surveys were conducted to value these 
items. To do this, the average of a sample of at least three 
different prices were considered for one equipment or 
furniture as suggested in the guidelines for cost data 
collection in the field in ACT consortium projects [32]. 
These sample prices were mainly obtained online in the 
case of equipment and in Ghanaian shops in the case of 
furniture. All costs were estimated for 2014 (taking into 
account the inflation rates when needed) and were con-
verted to US dollars.
The allocation of recurrent and capital costs to outpa-
tient visits was performed using the standard step down 
costing methodology [33]. First, all resources were allo-
cated to all cost centres using different allocation criteria 
suggested in the guidelines of ACT consortium projects 
[32] (step 1). Then, the overhead costs were allocated to 
support and final centres also using relevant allocation 
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criteria (step 2). Finally, support centres costs were allo-
cated to outpatient visits (step 3).
To differentiate cost per malaria, diarrhoea and sus-
pected pneumonia treatment in under-fives from the rest 
of the outpatient visits, a bottom up costing method was 
conducted. Interviews with staff captured self-reported 
time for doing a RDT and treating a case of malaria, diar-
rhoea and suspected pneumonia in children under-5 years 
of age. The average cost of RDT was taken from two mar-
ket surveys by the Global Fund and the Programme for 
Appropriate Technology in Health (PATH) [34, 35] which 
gave an average cost of US$0.35 plus a 10% of freight 
costs. Details of the drugs given were taken from a sam-
ple of patients (between 6–12 cases per disease in each 
CHPS). The cost of drugs used was the median price from 
a list of suppliers obtained from the International Drug 
Price Indicator Guide [36] with an addition of 10% freight 
costs as recommended by the guide.
Household costs
Household costs incurred when visiting a CBA or a 
CHPS facility were also divided into direct and indirect 
cost. Direct costs included cost per transport to provider 
and any other direct cost incurred at the provider such 
as drug costs or diagnostic costs. Indirect costs related 
to productivity loses and referred to time travelling to a 
CBA/CHPS and time spent at/with the provider. These 
costs were obtained from the household survey con-
ducted in 2014. Cost of carers time was calculated based 
on the agricultural labour wage [29, 30].
These household costs were obtained from the house-
hold survey conducted in 2014. Carers seeking care when 
their child was sick, were asked about all the different 
cost involved based on the different provider they vis-
ited. Therefore, household costs when visiting a CBA or 
a CHPS (or any other provider) were different and were 
accounted in the analysis.
Estimation of unit costs for treating a malaria, diarrhoea 
and suspected pneumonia case under the HBC and CHPS 
strategy from the societal perspective
Facility and programme costs were added to the house-
hold costs to obtain costs from the societal perspective 
under the HBC and CHPS strategies. Household costs 
related to drugs or RDT were also considered (even if 
they were already included when analysing the unit cost 
for the management of malaria, diarrhoea and suspected 
pneumonia from the HBC and CHPS perspective). 
Although the difference between including or excluding 
these costs was very little, as they are an extra cost for 
the household, it was decided to include them in the final 
cost.
Data from the survey showed that no deaths were 
reported after visiting a CBA or a CHPS in the Volta and 
Northern Regions. Reported referrals after visiting a CBA 
were 14.1 and 20.1% in the Volta and Northern Region, 
respectively, and 5.9 and 4.3% after visiting a CHPS com-
pound. However, 42 and 63% of carers sought care else-
where after using iCCM and 28 and 7.9% after using 
CHPS in the Volta and Northern Regions, respectively. 
This high proportion of carers visiting a second pro-
vider (particularly for the iCCM strategy) is important as 
it represents an extra cost to diagnose and treat a case. 
Therefore, costs due to this second visit to a provider 
Table 2 Cost per diagnosing and treating a malaria, diarrhoea and suspected pneumonia case under the iCCM strategy 
in the Volta and Northern Region in 2014 (US$)
Volta Region Northern Region
Malaria Diarrhoea Pneumonia Malaria Diarrhoea Pneumonia
Programme costs
 Training CBAs 881.43 125.57 40.73 18,756.66 25,024.98 9579.92
 Training supervisors 446.84 63.66 20.65 7062.53 9422.77 3607.17
 Supervision 0.00 0.00 0.00 1473.76 1966.28 752.72
 Training and IEC materials 60.93 8.68 2.82 1069.25 1426.58 546.11
 CBA drugs 36,088.88 837.48 1266.76 12,698.00 4343.24 5966.96
 ARI timers 0.00 0.00 0.00 0.00 0.00 658.15
 Registers 430.25 61.29 19.88 5961.00 7953.11 3044.57
 Time of CBAs 1426.16 210.89 68.40 484.11 645.90 247.26
 Drugs box 86.39 12.31 3.99 1448.60 1932.72 739.87
 Incentive package 1167.01 166.25 53.92 20,478.34 27,322.03 10,459.27
Total programme costs 40,587.89 1486.12 1477.14 69,432.25 80,037.61 35,602.01
Average cost per case 1.54 0.38 1.12 7.77 6.72 7.80
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were also taken into consideration and added to the unit 
cost for the diagnosis and management of malaria, diar-
rhoea and suspected pneumonia. To do this, the propor-
tion of carers that sought care to a health facility or to a 
licensed chemical seller because of malaria, diarrhoea or 
suspected pneumonia was multiplied by the cost of a sec-
ond visit. The cost of the second visit was calculated by 
adding programme/facility costs to household costs. This 
included: (1) the average of iCCM cost for diagnosing and 
treating a malaria, diarrhea and suspected pneumonia (if 
second provider was a licensed chemical seller or a drug 
peddler), or CHPS cost (if second provider was a health 
facility); (2) the average cost for traveling to the second 
provider and (3) the average money spent at the second 
provider visited. Taking into account that CHPS were 
the health facility more often used in this second visit, 
and that expenditures from other health facilities, from 
licensed chemical sellers or from drug peddlers were not 
available, it was believed that using CHPS and CBA cost 
was the best approach to calculate the cost for diagnosis 
and treating a case in the second visit.
Measurement of the cost‑effectiveness
The appropriate comparison of costs and effects between 
two programmes or interventions is the incremental 
cost-effectiveness ratio (ICER) [33]. In this study, rather 
than presenting ICERs numerically, the results were pre-
sented with the aim of helping to guide policy makers. 
Based on the cost-effectiveness plane [33], the following 
classifications were used to explore in which circum-
stances it might be appropriate to support the HBC strat-
egy with public funds:
a. iCCM dominates: iCCM is less costly and more 
effective.
b. iCCM is more costly and more effective.
c. iCCM is less costly and less effective.
d. iCCM is dominated: iCCM is more costly and less 
effective.
From a policy-maker’s perspective, if iCCM domi-
nates it would justify the support of this strategy with 
public funds, without necessarily saying that the CHPS 
strategy should be discontinued (as iCCM aims to com-
plement CHPS—and not to substitute them—as a strat-
egy to increase access to quality treatment). If iCCM is 
more costly and more effective, the decision on financing 
iCCM or not will depend on the government’s willing-
ness to pay, as there is no threshold to suggest how much 
extra money is reasonable to pay per extra case appro-
priately treated (while there is a suggested threshold on 
cost per DALYs averted or QALY gained that considers 
an intervention “highly attractive” or cost-effective [37]). 
If iCCM is less costly but less effective, it is not likely to 
be considered worthwhile using public funds unless the 
difference in effectiveness is minimal. If iCCM is domi-
nated, this suggests that the intervention should not be 
supported as it is currently being implemented.
Sensitivity analysis
To deal with uncertainty in this study a one-way sensi-
tivity analysis was conducted. The parameters chosen 
for the sensitivity analysis were discounting rates (3, 5 
and 7%), facility costs (average, lower and higher costs), 
different degrees of iCCM and CHPS utilization (based 
on the limits of the 95% CI obtained from the house-
hold survey) and iCCM effectiveness (50% increase and 
decrease).
Results
Calculation of the unit costs for diagnosing and treat-
ing a malaria, diarrhoea and suspected pneumonia case 
in children under-5 years of age from the health system, 
household and societal perspective is presented, followed 
by the cost-effectiveness and sensitivity analyses.
Unit cost for treating a malaria, diarrhoea and suspected 
pneumonia case from iCCM, CHPS, and households
Average iCCM programme costs in the Volta Region 
were lower when compared with those of the North-
ern Region: diagnosing and treating a malaria case costs 
US$1.54 and US$7.77, a diarrhoea case costs US$0.38 
and US$6.72 and a suspected pneumonia case cost 
US$1.12 and US$7.80 in the Volta and Northern Region, 
respectively (Table  2). The much higher iCCM costs in 
the Northern Region when compared with those of the 
Volta Region was mainly due to (1) higher costs for train-
ing and for the incentive package in the Northern Region 
(due to a higher number of CBAs); (2) a lower number of 
visits to sick children in the Northern Region (17,898 and 
30,839 visits in the Northern Region and Volta Region) 
and (3) a much lower number of IEC activities (177,484 
and 99 IEC activities conducted in the Volta Region and 
the Northern Region).
Across the Volta and the Northern Regions, the cost 
per diagnosing and treating a malaria case in a CHPS 
varied from US$4.65 to US$9.95; the cost per treat-
ing a diarrhoea case varied from US$3.05 to US$8.16 
and the cost per treating a suspected pneumonia cased 
varied from US$3.11 to US$8.79 (Table  3). When com-
pared with the Northern Region, the Volta Region had 
the lower and higher costs per malaria, diarrhoea and 
suspected pneumonia case diagnosed and treated across 
both regions. These differences in the Volta Region 
were mainly due to the existence of a bigger facility with 
smaller reported activity compared to a smaller facility 
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with higher reported activity. In the Northern Region, 
the micro-costing exercise showed that the large differ-
ences observed in diagnosing and treating a malaria case 
in the two CHPS sampled were mainly due to the use of 
ACT syrup in one of the CHPS (which cost US$ 0.1/ml) 
instead of ACT tablets (which costs US$ 0.01/tablet).
Diagnosing and treating malaria was found to be 
more costly than diarrhoea or suspected pneumonia 
in 3 out of 4 CHPS facilities. All three diseases needed 
similar resources in terms of building, furniture and 
equipment. However, in the case of malaria the cost 
increased because of the time invested in doing the 
RDT and the laboratory costs. In addition, and as men-
tioned above, the cost of ACT syrup was higher than 
the cost of ACT tablets and higher than ORS (0.07/
sachet), zinc (0.02/tablet) or amoxicillin (0.004/ml). 
Household costs represent the cost of time used to 
travel to the provider, the money spent on travel, the 
cost of time spent with the provider, the money spent at 
the provider in terms of food and other costs involved 
such as paying for the service or for drugs. As expected, 
household costs were higher when visiting a CHPS 
facility than when visiting a CBA, particularly because 
of longer distances from households to a CHPS facil-
ity than to a CBA, higher cost of transport and longer 
time at a CHPS facility than with a CBA. Household 
costs ranged from US$0.04 when visiting a CBA in the 
Northern Region (corresponding to a 0.4% of the total 
cost per case) to US$1.54 when visiting a CHPS in the 
Volta Region (corresponding to 20.6% of the total cost 
per case) (Table 4).
Unit cost for treating a malaria, diarrhoea and suspected 
pneumonia case from the societal perspective
To obtain costs from the societal perspective, household 
costs were added to programme costs of the iCCM and 
CHPS strategies (Table 5).
Costs involved due to a second visit to a provider 
after visiting a CBA or a CHPS facility were added to 
programme/facility costs. In the Volta Region, average 
costs for this second visit were US$3.34 and US$0.41 
per malaria case treated under the iCCM and CHPS 
strategy respectively; US$0.41 and US$0.11 per diar-
rhoea case treated under the iCCM and CHPS strategy 
and US$0.14 and US$0.02 per suspected pneumonia case 
treated under the iCCM and CHPS strategy respectively. 
In the Northern Region, average costs for the second 
visit to a provider were US$1.56 and US$0.61 per malaria 
case under the iCCM and CHPS strategy respectively; 
US$1.53 and US$0.16 per diarrhoea case treated under 
the iCCM and CHPS strategy and US$0.66 and US$0.001 
per suspected pneumonia case treated under the iCCM 
and CHPS strategy, respectively.
After adding household costs and those of the second 
visit to a provider, the cost per diagnosing and treating a 
malaria case under the iCCM strategy was US$4.96 and 
US$9.37 in the Volta and Northern Regions and US$9.52 
and US$8.07 in a CHPS in the Volta and the Northern 
Regions; to treat a diarrhoea case costs US$0.88 and 
US$8.36 under the iCCM in the Volta and Northern 
Regions and US$7.25 and US$5.54 in a CHPS in the Volta 
and the Northern Regions. Finally, treating a suspected 
pneumonia case cost US$1.33 and US$8.50 under the 
iCCM strategy in the Volta and the Northern Regions 
and US$7.45 and US$6.73 in a CHPS in the Volta and the 
Northern Regions, respectively.
Cost‑effectiveness analysis
Tables 6, 7 and 8 presents the average cost per case appro-
priately diagnosed and treated (average cost per malaria, 
diarrhoea and suspected pneumonia cases appropriately 
diagnosed and treated according to protocol in a group 
of 100 eligible children, meaning that those that needed 
the treatment received it, and those that did not need the 
treatment did not receive it) and the ICERs. Due to the 
low numbers of children visiting a CBA in the Northern 
Region [19], the iCCM data of the Northern Region were 
excluded from this analysis.
In the Volta Region, iCCM was more attractive than 
CHPS not only for the appropriate diagnosis and treat-
ment of malaria, but also for the appropriate treatment 
of diarrhoea and suspected pneumonia. Note that even 
though the GFATM only provides ACT drugs for the 
iCCM strategy in the Volta Region, CBAs received train-
ing for the management of the three diseases [19]. If no 
drugs were available to treat a diarrhoea and pneumonia 
case (CBAs were provided with ORS, zinc and amoxicil-
lin in 2013), CBAs were supposed to refer cases for fur-
ther management, and this referral was also considered 
as appropriate treatment.
The average cost per malaria, diarrhoea and suspected 
pneumonia case appropriately diagnosed and treated 
was lower under the HBC than under the CHPS strategy. 
iCCM had lower costs than CHPS to diagnose and treat 
malaria, diarrhoea and suspected pneumonia cases while 
the effectiveness of both strategies was similar or slightly 
higher under the iCCM strategy (Tables 6, 7, 8).
The ICERs showed that HBC dominates CHPS for the 
prompt ACT or quinine treatment of malaria, for the 
treatment of diarrhoea with ORS or referred and for the 
treatment of diarrhoea with ORS and zinc (or referred). 
In the case of the management of suspected pneumonia, 
HBC was less costly and had the same effectiveness of 
CHPS. The management of malaria with ACT or quinine 
(including prompt and not prompt treatment) merits a 
further comment. Treating a malaria case under iCCM 
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was less costly (US$119.04 versus US$182.30 were used 
to treat 100 children under the iCCM and CHPS strat-
egy, respectively) but slightly less effective than under the 
CHPS strategy (28 and 30% of cases were treated accord-
ing to protocol under iCCM and CHPS, respectively). 
Due to the small difference in effectiveness and the larger 
difference in cost, it can be concluded that iCCM was 
also cost-effective for the treatment of malaria with ACT 
or quinine when the promptness in treatment was not 
considered.
Sensitivity analysis
The one-way sensitivity analysis explored how vary-
ing specific values influenced the average cost per case 
Table 6 Cost-effectiveness for  diagnosing and  treating malaria per  100 eligible children from  de societal perspective 
in 2014 (US$)
a Source Additional file 1
Variables Volta Region Northern Region
iCCM CHPS iCCM CHPS
Number of eligible children for treatment 100 100 100
Number treated with ACT or  quininea 24 19 30
Number treated with prompt ACT or quinine 17 4 23
Number treated according to protocol (ACT or quinine) 28 30 35
Number treated according to protocol (prompt ACT or quinine) 21 15 27
Costs per 100 children (ACT or quinine) US$119.04 US$182.30 US$244.57
Cost per child treated according to protocol (ACT or quinine) US$4.25 US$6.12 US$7.09
Cost per child treated according to protocol (prompt ACT or quinine) US$5.58 US$12.24 US$8.92
Incremental costs per 100 children (ACT or quinine) US$63.26
Incremental effect per 100 children (ACT or quinine) 2
Incremental cost‑effectiveness ratio (ACT or quinine) iCCM is less costly and less effective
Incremental costs per 100 children (prompt ACT or quinine) US$63.26
Incremental effect per 100 children (prompt ACT or quinine) 6
Incremental cost‑effectiveness ratio (prompt ACT or quinine) iCCM is dominant
Table 7 Cost-effectiveness for diagnosing and treating diarrhoea per 100 eligible children from de societal perspective 
in 2014 (US$)
a Source Additional file 2
b Appropriate treatment for diarrhoea under the iCCM strategy in the Volta Region includes those treated with ORS and zinc or referred for further management. The 
cost per treatment of those referred is included to allow comparison with CHPS
Variables Volta  Regionb Northern Region
iCCM CHPS iCCM CHPS
Number of eligible children for treatment 100 100 100
Number treated with ORS (or referred)a 8 11 7
Number treated with ORS and zinc (or referred) 11 7 4
Number treated according to protocol (ORS or referred) 59 57 62
Number treated according to protocol (ORS and zinc) 54 43 59
Costs per 100 children (ORS) US$6.84 US$83.20 US$38.88
Cost per 100 children (ORS and zinc) US$9.78 US$47.54 US$19.44
Cost per child treated according to protocol (ORS or referred) US$0.12 US$1.45 US$0.62
Cost per child treated according to protocol (ORS and zinc) US$0.18 US$1.12 US$0.33
Incremental costs per 100 children (ORS or referred) US$76.35
Incremental effect per 100 children (ORS or referred) 2
Incremental cost‑effectiveness ratio (ORS or referred) iCCM is dominant
Incremental costs per 100 children (ORS or referred) US$37.76
Incremental effect per 100 children (ORS or zinc) 11
Incremental cost‑effectiveness ratio (ORS and zinc) iCCM is dominant
Page 13 of 18Escribano Ferrer et al. Malar J  (2017) 16:277 
appropriately diagnosed and treated from the societal 
perspective in both strategies as well as the ICERs. For 
simplicity in presenting the data, only one ICER per dis-
ease was included, the one that better reflects the adher-
ence to guidelines (prompt ACT for malaria, ORS and 
zinc for the management of diarrhoea and amoxicillin for 
the management of suspected pneumonia). iCCM in the 
Volta Region remained more cost-effective than CHPS 
for the diagnosis and treatment of malaria, diarrhoea and 
suspected pneumonia cases when using different facility 
costs, different discount rates and different iCCM and 
CHPS utilization. When iCCM effectiveness was reduced 
by 50%, iCCM remained cost-effective only for the treat-
ment of diarrhoea (Table 9).
Discussion
Before the adoption of the iCCM and CHPS strategies in 
the Ghana Health System, RCT were conducted to assess 
their efficacy in Ghana [13, 16]. In addition, another 
study was conducted to assess the cost-effectiveness of 
two strategies of HBC [38], although without presenting 
the cost per fever treated under the standard care. The 
current evaluation used data from an observational study 
to analyse the cost-effectiveness of iCCM and CHPS 
strategies after 2 and 8 years of iCCM implementation in 
the Volta and the Northern Regions respectively for the 
treatment of malaria, diarrhoea and suspected pneumo-
nia in children under-five. Results from this evaluation 
may be used to improve iCCM and CHPS implementa-
tion and to guide policy makers in the discussion about 
long term financing of iCCM.
This study brings more light to the scarce evidence 
on iCCM cost-effectiveness. Three comparable stud-
ies were found on the cost-effectiveness of malaria HBC 
versus standard care conducted in Ghana [38], Uganda 
[39] and Zambia [40]. No studies were found on the 
cost-effectiveness of treatment of diarrhoea and/or pneu-
monia delivered through iCCM. A systematic review that 
looked at the effect of community-case management of 
pneumonia in Africa concluded that there is a lack of evi-
dence on its efficacy [41].
Results from the current study showed that iCCM in 
the Volta Region was more cost effective than CHPS for 
the management of malaria, diarrhoea and suspected 
pneumonia in children under-five, even after the sensi-
tivity analysis modifying health facility costs, discount 
rates and service utilization. However, if the iCCM effec-
tiveness was reduced by 50%, HBC remained less costly 
but less effective than CHPS and therefore, less cost-
effective. These results are coherent with the three stud-
ies mentioned above, which concluded that iCCM was 
more cost-effective than the standard care (defined as 
the care received from a health facility). The RCT con-
ducted in the south of Ghana [38] and the Markov mod-
elling using data from Uganda [42] looked at the cost per 
DALY averted. The study conducted in Zambia [40] used 
case appropriately diagnosed and treated as the effective-
ness measure, concluding that malaria iCCM was more 
cost-effective than the standard care. Some differences 
however can be seen between the Zambia study and the 
current study: the Zambia analysis was done from the 
provider perspective, used registries instead of survey 
data to assess effectiveness, and RDTs were used within 
the iCCM strategy. Excluding household costs could bias 
results in favour of CHPS (the current study showed 
that household costs were higher when visiting a CHPS 
than a CBA). Using registries instead of surveys to col-
lect effectiveness data could also introduce differences: 
registers might suffer from incomplete reporting and sur-
vey data might suffer from recall bias and misinterpreta-
tion of symptoms. Using an RDT for malaria diagnosis in 
iCCM could increase iCCM cost (due to staff time and 
Table 8 Cost-effectiveness for diagnosing and treating suspected pneumonia per 100 eligible children from de societal 
perspective in 2014 (US$)
a Source Additional file 3
b Appropriate treatment for suspected pneumonia under the iCCM strategy in the Volta Region includes those treated with amoxicillin or referred for further 
management. The cost per treatment of those referred is included to allow comparison with CHPS
Variables Volta  Regionb Northern Region
iCCM CHPS iCCM CHPS
Number of eligible children for treatment 100 100 100
Number treated with amoxicillin or  cotrimoxazola 15 16 23
Number treated according to protocol 72 72 73
Costs per 100 children US$19.87 US$122.13 US$156.44
Cost per child treated according to protocol US$0.274 US$1.693 US$2.13
Incremental costs per 100 children US$102.25
Incremental effect per 100 children 0
Incremental cost‑effectiveness ratio iCCM is less costly and the same effective than CHPS
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Table 9 Sensitivity to  selected parameters of  the cost-effectiveness ratio and  the incremental cost-effectiveness ratio 
(ICER) for treating malaria, diarrhoea and suspected pneumonia in children under-five under iCCM and CHPS in the Volta 
Region
Indicators iCCM CHPS iCCM CHPS iCCM CHPS
Average facility cost More costly facility Less costly facility
Costs per 100 children (ACT or 
quinine)
119.0 182.3 141.1 234.0 97.0 130.6
Number treated according to protocol 
(prompt ACT or quinine)
21 15 21 15 21 15
Incremental cost‑effectiveness ratio 
(prompt ACT or quinine)
iCCM dominates iCCM dominates iCCM dominates
Cost per 100 children (ORS and zinc) 9.8 47.5 11.2 64.4 8.3 30.7
Number treated according to protocol 
(ORS and zinc)
54 43 54 43 54 43
Incremental cost‑effectiveness ratio 
(ORS and zinc)
ICCM dominates iCCM dominates iCCM dominates
Costs per 100 children (amoxicillin) 19.9 122.1 20.5 168.9 19.1 75.6
Number treated according to protocol 
(amoxicillin)
72 72 72 72 72 72
Incremental cost‑effectiveness ratio 
(amoxicillin)
iCCM less costly/same effectiveness iCCM less costly/same effectiveness iCCM less costly/same effec‑
tiveness
3% discount rate 5% discount rate 7% discount rate
Costs per 100 children (ACT or 
quinine)
119.04 182.30 121.20 187.66 127.68 202.60
Number treated according to proto‑
col (prompt ACT or quinine)
21 15 21 15 21 15
Incremental cost‑effectiveness ratio 
(prompt ACT or quinine)
iCCM dominates iCCM dominates iCCM dominates
Cost per 100 children (ORS and zinc) 9.78 47.54 9.78 48.46 9.89 49.84
Number treated according to proto‑
col (ORS and zinc)
54 43 54 43 54 43
Incremental cost‑effectiveness ratio 
(ORS and zinc)
iCCM dominates iCCM dominates iCCM dominates
Costs per 100 children (amoxicillin) 19.87 122.13 19.87 124.59 19.87 127.87
Number treated according to proto‑
col (amoxicillin)
72 72 72 72 72 72
Incremental cost‑effectiveness ratio 
(amoxicillin)
iCCM less costly/same effectiveness iCCM less costly/same effectiveness iCCM less costly/same effec‑
tiveness
Average utilization Higher utilization Lower utilization
Costs per 100 children (ACT or 
quinine)
119.04 182.30 110.40 166.21 144.00 226.91
Number treated according to protocol 
(prompt ACT or quinine)
21 15 21 15 21 15
Incremental cost‑effectiveness ratio 
(prompt ACT or quinine)
iCCM dominates iCCM dominates iCCM dominates
Cost per 100 children (ORS and zinc) 9.78 47.54 8.67 43.48 12.78 50.23
Number treated according to protocol 
(ORS and zinc)
54 43 54 43 54 43
Incremental cost‑effectiveness ratio 
(ORS and zinc)
iCCM dominates iCCM dominates iCCM dominates
Costs per 100 children (amoxicillin) 19.87 122.13 14.64 112.13 36.46 128.85
Number treated according to protocol 
(amoxicillin)
72 72 72 72 72 72
Incremental cost‑effectiveness ratio 
(amoxicillin)
iCCM less costly/same effectiveness iCCM less costly/same effectiveness iCCM less costly/same effec‑
tiveness
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laboratory costs) but drug costs might be reduced (if 
CHW adhere to RDT results).
The cost-effectiveness analysis was not conducted in 
the Northern Region due to the low numbers of carers 
visiting a CBA. However, the cost analysis showed that 
iCCM programme costs in the Northern Region were 
higher than those in the Volta Region and higher than 
CHPS costin the Volta and in Northern Region, particu-
larly due to the higher number of CBAs registered doing 
few preventive and curative activities.
Long term financing is a cornerstone of iCCM, often 
financed by health partners without a clear sustainabil-
ity strategy. However, if iCCM is an effective and cost-
effective intervention, other financial plans must be 
considered. In Ghana, the NHIS pays health providers 
for services included in the insurance benefit package. 
A condition to include a service into the NHIS ben-
efit package is its cost-effectiveness. The current study 
showed that the curative component of the iCCM strat-
egy in the Volta Region was more cost-effective than 
CHPS. In addition, iCCM contributes to health equity as 
it was able to reach the poorest in the Volta Region [19], 
and it was associated with disease knowledge and healthy 
behaviours in the Northern Region.
All these points should make the iCCM strategy 
“attractive” to be included in the NHIS benefit package. 
However, the NHIS must have the money to finance this 
strategy without increasing the already high burden of 
the insurance expenditure. In the period 2009–2013 the 
NHIS expenditures exceeded revenues [43–45]. The 2014 
and 2015 reports were not available. Revising the NHIS 
benefit package as planned in 2014 [46] and consider-
ing iCCM strategy among the possible benefits based 
on the results of this study could be a positive way for-
ward. From the point of view of implementation, it is 
important to reflect on how the NHIS could reimburse 
iCCM activities. CHPS are facilities registered under the 
NHIS. CBAs curative activities reported to CHPS could 
be reimbursed by the NHIS as activities related to CHPS, 
which is informally happening already in some districts. 
If the preventive component of iCCM is also consid-
ered (which is likely to be cost-effective when compared 
to CHPS-because of its lower costs and higher effect on 
disease knowledge and health behaviour, although not 
assessed here), some IEC activities, particularly those 
done in partnership with CHPS under Community, IMCI 
could also be reimbursed by the NHIS. This could help 
the sustainability of iCCM, retain CBAs and improve 
the quality of the intervention. However, control meas-
ures must be put in place to avoid reporting false activ-
ity. Another issue to be considered is the acceptability, 
particularly of the CHPS and the NHIS. An acceptability 
study should be conducted to assess the perceptions of 
different stakeholder.
Limitations of the study
The effectiveness measure in this study was obtained 
from a cross sectional study. Effectiveness data in eco-
nomic evaluations are often recommended to be from 
RCT although there are limitations such as the compre-
hensiveness (only one source of data) and the short time 
horizons. To overcome these limitations, there is now 
a tendency to use data from systematic reviews or even 
better, from decision analytic modelling [33]. This is true 
if one wants to prove the efficacy and efficiency of a new 
intervention. But if one wants to evaluate the effective-
ness and efficiency of a proven intervention in a real life 
routine setting, meaning evaluating its costs and effects 
during actual implementation as in an ex-post HTA, then 
data from observational studies are more relevant [3, 4, 
33] and have been used in several studies in the UK, Asia 
and Africa [40, 47–51].
Table 9 continued
Average effectiveness Higher effectiveness Lower effectiveness
Costs per 100 children (ACT or quinine) 119.04 182.30 111.86 178.28 88.40 186.13
Number treated according to protocol (prompt 
ACT or quinine)
21 15 31 15 11 15
Incremental cost‑effectiveness ratio (prompt ACT 
or quinine)
iCCM dominates iCCM dominates iCCM is less costly and less effective
Cost per 100 children (ORS and zinc) 9.78 47.54 6.82 47.15 14.40 47.87
Number treated according to protocol (ORS and 
zinc)
54 43 59 43 49 43
Incremental cost‑effectiveness ratio (ORS or zinc) iCCM dominates iCCM dominates iCCM dominates
Costs per 100 children (amoxicillin) 19.87 122.13 19.55 121.97 19.97 122.30
Number treated according to protocol (amoxicil‑
lin)
72 72 80 72 65 72
Incremental cost‑effectiveness ratio (amoxicillin) iCCM dominates iCCM dominates iCCM is less costly and less effective
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The effectiveness measure used was ‘case appropriately 
diagnosed and treated’ as a proxy indicator of child mor-
tality. Even though intermediate outputs are admissible 
in cost-effectiveness analysis (although it is better to use a 
final health outcome) [33], this measure might bring diffi-
culties when summarizing results from each of the three 
diseases evaluated. However, the fact that results were 
similar among the three diseases evaluated (iCCM was 
more cost-effective for the treatment of malaria, diar-
rhoea and suspected pneumonia) made the interpretation 
easier. In addition, the effectiveness measure used does 
not have a threshold to define whether an intervention 
is cost-effective or not. Ideally, the government should 
be questioned about their willingness to pay per extra 
case appropriately treated. However, as the iCCM strat-
egy was less costly than CHPS, this limitation was solved. 
Case appropriately diagnosed and treated measures the 
quality of care given as it refers to adherence to guide-
lines. However, it does not consider the outcome of death 
or disability (although the cost for visiting a second pro-
vider was considered in case the child did not recover). 
Even it would not be expected that not considering death 
and disability might influence the results—no deaths or 
disability were reported—using DALYs or QALYs might 
have solved the issue of the different end points of treat-
ment. In addition, the use of DALYs/QALYs might have 
allowed a comparison of the study results with other dis-
eases and studies.
Case appropriately diagnosed in this study refers to 
adherence to guidelines and not to adherence to micros-
copy results which is the gold standard method for 
diagnosing malaria (which cannot be performed at this 
community level). This means that the appropriate diag-
nosis of malaria under the iCCM strategy refers to a child 
with fever, while in the CHPS refers to a child with a 
positive RDT or a child with fever if not RDT was per-
formed. Although some fever cases might be misclassi-
fied as malaria cases, this is something to consider when 
revising the iCCM guidelines but not in this current 
study (which objective is to assess the iCCM and CHPS 
implementation and the adherence to guidelines).
Data from the cross-sectional study brought relevance 
to the evaluation but also brought limitations. Carers of 
sick children chose their providers based on different cri-
teria (such as proximity, trust, availability or perceived 
severity of disease), reflecting the actual utilization of 
the services. This self-selection also affected the cost-
effectiveness analysis: few carers of sick children chose 
to visit a CBA in the Northern Region. Due to these low 
numbers of carers visiting a CBA in the Northern Region 
it was not possible to conduct the cost-effectiveness 
analysis. Self-selection is a factor to be considered when 
addressing cost- effectiveness. Children would have been 
taken to a CHPS if their disease was perceived to be more 
severe by their carer, reducing the cost-effectiveness of 
CHPS compared to iCCM. However, this study aimed to 
assess the cost-effectiveness of iCCM in the routine sys-
tem, and therefore, this self-selection should be consid-
ered as part of the system and not as a source of bias.
Sources of facility costs came from data of two CHPS 
in the Volta Region and two in the Northern Region. 
Although the analysis took into consideration average 
costs, and higher and lower facility cost for the sensitiv-
ity analysis, it would have been better to have at least one 
more CHPS in each region to have a better representa-
tion of CHPS costs. Unfortunately, it was not possible to 
add another CHPS to the cost analysis.
Finally, different epidemiological burden would not be 
expected to influence results, as the target population 
was children with symptoms. However, finding these 
children when doing the data collection was easier in the 
Northern Region as the prevalence of the three diseases 
was higher.
Conclusions
This study added to the scarce evidence on the iCCM 
cost-effectiveness. iCCM for treating malaria, diarrhoea 
and suspected pneumonia in children under-5  years 
of age was more cost-effective than treatment through 
CHPS in the Volta Region. High programme costs in 
addition to low curative and preventive activities made 
the HBC strategy in the Northern Region more costly 
than in the Volta Region. A revision of the iCCM strat-
egy in the Northern Region is needed to improve its 
cost-effectiveness. This study supports the need for a 
long-term financing strategy, such as inclusion of iCCM 
in the NHIS benefit package. However, a revision of the 
NHIS benefit package and an acceptability study must 
be conducted before making such a decision. Then, the 
appropriateness of a pilot study including iCCM services 
in the NHIS could be considered.
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